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ABSTRACT
Sarcopenia and diabetes are two conditions that reflect ongoing changes in global health
trends: aging and obesity. Sarcopenia affects approximately 10-40% of the global population and
type II diabetes affects around 415 million individuals (6.28% globally), with obesity
contributing to a majority of the cases [1, 2]. Currently, approximately 9.3% of the population
(727 million individuals) is aged 65 years or older; this number is predicted to reach 16% of the
global population (around 1.5 billion individuals) in 2050 [3]. Many developed countries are
undergoing demographic population pyramid rearrangements whereby an increasingly aging
population must be supported by a shrinking youth cohort. Sarcopenia involves progressive loss
of muscle mass as a natural, physiological result of the aging process and is proving a pressing
concern for the modern-day, aging population, as it may contribute to increased risk of falls,
accidents, hospitalization, decreased range of motion and mobility, increased comorbidities, and
overall decreased quality of life, particularly in elderly populations. Type II diabetes occurs
when normal insulin function and regulation is impaired. It often features symptoms of
hyperglycemia, insulin resistance, polydipsia, polyuria, and fatigue and is among one of the most
alarming metabolic conditions for the modern world. Both sarcopenia and diabetes involve
complex metabolic disturbances. Several studies have established a reciprocal relationship
between sarcopenia and diabetes, where the presence of one condition influences or exacerbates
the other. However, to the best of our knowledge, no studies have analyzed if a difference in the
strength of the relationship exists among different ethnic groups. The main objective of this
project is to conduct a review and meta-analysis to further explore the relationship between
sarcopenia and diabetes, to determine whether a statistically significant difference in the strength
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of the relationship exists among different ethnic groups, and to suggest future research directions
and perspectives based on given results.
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INTRODUCTION
A rapidly evolving, fast-paced, and technologically inclined global stage has given rise to
an increasingly alarming incidence of chronic, metabolic diseases and associated physiological,
economic, and social healthcare burdens. Diabetes is among one of the world’s leading causes of
morbidity, as well as mortality, and has cost the U.S. alone nearly $327 billion in 2017 [4]. Over
the past couple centuries, the average human lifespan has dramatically increased. Consequently,
the number of adults over the age of 65 has increased in many developed countries. In the year
2020, there were 727 million individuals aged 65 years and older, representing approximately
9.3% of the world population [3]. Globally, individuals 65 and older is estimated to rise from
9.3% of the world population in 2020 to 16% of the total population in 2050 (roughly 1.5 billion
elderly persons) [3]. Sarcopenia represents a natural—albeit, in the modern world, concerning—
age-related decline in muscle mass that may contribute to other comorbid diseases. Several
studies have identified a reciprocal relationship between sarcopenia and diabetes: the presence of
sarcopenia increases a patient’s risk for developing diabetes and, transitively, the presence of
diabetes increases a patient’s risk for augmenting sarcopenic declines in muscle mass [1-3, 5-12].
Previous studies have established a relationship between sarcopenia and diabetes; however, to
the best of our knowledge, no studies have evaluated the strength of the relationship between
sarcopenia and diabetes among different ethnicities. This study aims to conduct a meta-analysis
to determine if a difference exists in the strength of the sarcopenia-diabetes relationship across
different ethnic groups.
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WHAT IS SARCOPENIA?
Sarcopenia is characterized by a progressive loss in skeletal muscle mass that is often
accompanied by a decrease in muscle strength and performance [13-15]. The word is derived
from the Greek root “sarx”, meaning flesh, and “penia”, meaning loss, translating to “loss of
flesh” [13] [16]. Sarcopenia most commonly presents in older age and, in many cases, is a
biologically inevitable result of the aging process [1, 13]. Depending on the definition used for
diagnosis, the global prevalence of sarcopenia ranges from 10-40% of the world population [1,
2].
Around the age of 50, the annual rate of muscle mass loss is estimated to be between 12%, with a concurrent 1.5% annual decrease in muscle strength between 50 and 60 years of age.
Other studies have reported reductions in muscle mass and functioning beginning around the
ages of 30 or 40 [11, 17]. After 60 years, muscle strength declines at a rate of 3% a year [11, 17].
Muscle strength often declines at a more rapid rate than muscle mass [11, 18]. After 70 years of
age, it is estimated that muscle mass decreases around 15-25% every ten years [3].
There are four main causes for muscle loss: sarcopenia, anorexia, cachexia, and
dehydration [17, 19]. Among these, cachexia should be distinguished from sarcopenia. Cachexia
(Greek for “bad condition”) involves an underlying medical disease state that produces weight
loss, increased protein catabolism, and altered metabolic changes that may result in muscle loss.
Cachexia may result in sarcopenia, but sarcopenia does not necessarily result in cachexia [16, 1921]. Dynapenia, which is characterized by loss of muscle power, should also be distinguished
from sarcopenia, as it has recently been shown that muscle size plays less of a significant role in
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reducing muscular force generation as opposed to control over functional motor units recruited
for muscle action [22].
Two types of sarcopenia are recognized: primary and secondary sarcopenia. Primary
sarcopenia is categorized as the natural, persevering loss of muscle mass that occurs as one ages
[11, 20]. Secondary sarcopenia, conversely, involves external and environmental factors such as
lifestyle, physical activity, diet, comorbid diseases, or other idiopathies [11, 20]. Primary
sarcopenia may be exacerbated by secondary sarcopenia and vice versa.
Sarcopenic obesity is a subtype of sarcopenia that is characterized by loss of lean body
mass with concurrent maintenance of fat mass or increased fat mass relative to lean body mass
[20]. This condition is becoming increasingly prevalent with the growing percentage of both
aging and overweight or obese individuals in the population. Sarcopenic obesity represents a
dangerous intersection of metabolic complications in which the causes and effects of sarcopenia
and obesity work to potentiate each other, such that the metabolic disturbances of one
synergistically increase the disturbances of the other [7, 10, 20]. Presently, sarcopenic obesity
represents an increasingly pressing chronic disease of the modern world; it marks a crossroad
between an aging population with a sedentary lifestyle and a modern diet high in processed
sugars, fat, and refined carbohydrates that has been conducive to weight gain and metabolic
diseases. To address the rising concern regarding sarcopenia, the condition was issued the
International Classification of Diseases (ICD) code ICD-10-CM (M62.84) in 2016 [3, 23, 24].
This officially recognized sarcopenia as a disease, thereby prioritizing clearer criterion for
diagnosis as well as increased interest in sarcopenia research and drug development.
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Currently, the molecular mechanism behind sarcopenia has not been clearly defined.
There is no defining cause of sarcopenia, though age remains a major contributing factor.
Sarcopenia is a multifactorial disease that may result from age-induced metabolic changes,
muscular disuse (as with those on bedrest or those with prolonged sedentary lifestyles), disrupted
endocrine functioning, inflammation, motor neuron loss, chronic inflammation, chronic diseases,
osteoporosis, metabolic disturbances (as with metabolic diseases), insulin resistance, genetic
factors, and inadequate nutrition, among other factors [5, 16, 19, 24-27].
Risk factors for sarcopenia include old age, sedentary behavior, gender, and comorbid
diseases [16, 20]. Sarcopenia has shown to be comorbid with obesity, insulin resistance, diabetes,
dyslipidemia, hypertension, osteopenia, osteoporosis, gastrointestinal reflux disease, coronary
artery disease, and osteoarthritis. Moreover, many diseases that are comorbid with sarcopenia
involve disturbances to metabolic function [20, 25, 27, 28].
The elderly population is particularly at risk for sarcopenia. Many elderly persons live in
nursing homes or assisted living facilities where physical activity is limited, and most daily
activities are sedentary. Increased sedentation in the elderly is both the cause of or further
reinforced by a declining range of motion, increased susceptibility to falls and fractures, and
health conditions that impair mobility and functionality (i.e., osteoporosis, osteoarthritis,
rheumatoid arthritis) [7, 8, 15, 16]. Additionally, appetite may wane in older age; decreased
caloric—specifically protein—intake may result in muscle wasting and loss of mass. Sarcopenia
has been associated with increased risk of falls, accidents, limited mobility, disability, increased
hospital admission, decreased quality of life, and increased mortality [7, 8, 15, 16]. Increased risk
of bone weakness and fracture (coupled with increased risk of injury) may deter many elderly
4

individuals from partaking in muscle-strengthening physical activities—a self-perpetuating cycle
that can worsen the progression, symptoms, and outcome of sarcopenia, as well as decrease
overall quality of life.
How is Sarcopenia Diagnosed?

Over the years, several region-specific definitions and recommendations for diagnosing
sarcopenia have been proposed, but a cohesive, comprehensive set of diagnostic criteria has yet
to be established. Three main criteria are commonly evaluated in determining the presence of
sarcopenia: (1) muscle mass, (2) muscle strength, and (3) muscle function or performance [16,
20, 26]. The two main diagnostic definitions, as defined by EWGSOP and AWGS, are included
below.
Definition as Established by the European Working Group on Sarcopenia in Older People
(EWGSOP)
The EWGSOP definition for sarcopenia evaluates the extent of low skeletal muscle mass
as well as either low muscle strength (as measured by tests for handgrip strength) or low muscle
performance (as measured by tests involving walking speed) [16, 20].
Suggested measurements for muscle mass include bioimpedance analysis (BIA), dualenergy x-ray absorptiometry (DEXA) scans, magnetic resonance imaging (MRI), and computed
tomography (CT) imaging. Muscle strength may be measured by assessing handgrip strength, the
extent of knee flexion or extension, or peak expiratory flow. Physical performance can be
evaluated with the short physical performance battery (SPPB) test, which involves measuring
balance, gait, strength, and endurance via quantifying one’s ability to stand with feet together
and measuring the time to walk 8 feet, the time to rise from a chair, and the time to return to a
5

seated position five times. The cutoff point for classifying an individual at risk for sarcopenia is
established as a gait speed of less than 0.8 m/s [16].
Standard sarcopenia is diagnosed when an individual possesses low muscle mass along
with low muscle strength or low muscle performance. Severe sarcopenia is diagnosed when all
three criteria are identified as low. The EWGSOP definition also provides classification for a
‘presarcopenia stage’ that includes the presence of low muscle mass and unimpaired muscle
strength or performance [16, 20].

Table 1. Evaluation of stage of sarcopenia based on established standards by the European Working Group
on Sarcopenia in Older People (EWGSOP).

Stage
Presarcopenia
Sarcopenia
Severe sarcopenia

Muscle Mass

Muscle Strength

Low
Low
Low

Normal
Low
Low

Muscle
Function/Performance
Normal
or
Low
Low

Adapted from “Sarcopenia: European consensus on definition and diagnosis: Report of the European Working
Group on Sarcopenia in Older People” by Cruz-Jentoft et al., 2010. Copyright 2010 by Cruz-Jentoft et al. [16]

Definition as Established by the Asian Working Group for Sarcopenia (AWGS)
According to the AWGS, sarcopenia is diagnosed by loss of muscle mass, as well as low
muscle strength and/or low physical performance [14, 15].
Muscle mass cut-offs for sarcopenia using DEXA or BIA have established: less than 7.0
kg/m2 in men and less than 5.4 kg/m2 in women when utilizing DEXA measurements; less than
7.0 kg/m2 in men and less than 5.7 kg/m2 in women when utilizing BIA measurements. Muscle
strength is quantified through measuring handgrip strength; a handgrip strength of less than 28
kg for men and less than 18 kg for women indicates low muscle strength. Low muscle
6

performance is defined by a speed of less than 1.0 m/s when tested on a 6-meter walk, as well as
an SPPB score of less than 9 or a 5-time chair stand test of greater than 12 seconds [14, 15].
Sarcopenia Prevalence and Trends
Depending on the standards of diagnosis used, sarcopenia prevalence ranges from 5-13%
for those from 65 to 70 years old and 11-50% for those older than 80 years of age [20]. In 2010,
approximately 50 million individuals were estimated to be affected by sarcopenia; this number is
expected to increase to over 200 million in the next four decades, representing staggeringly large
and increasing healthcare costs associated with an aging population [20].
Gender differences in sarcopenia progression have been observed. Males have distinctly
higher levels of testosterone, as well as a higher percentage of muscle mass compared to females.
Estrogen, which persists in higher concentrations in females relative to testosterone, promotes fat
storage, while testosterone promotes muscle synthesis. As individuals age, sex steroid
concentrations decrease; however, androgen decline is slower in males compared to females.
More rapid decline of anabolic hormones in females may be responsible for higher sarcopenia
prevalence in older women (ages 60 and older) [9, 29].
Globally, population subsets observed to have a higher prevalence of sarcopenia include
men, older-aged adults, individuals with lower body mass index (BMI) measurements,
individuals residing in assisted living communities or nursing homes, and individuals with lower
education level attainment [25]. Sarcopenia prevalence appears to differ when examined across
different ethnic groups: Asian populations demonstrated a higher prevalence of sarcopenia, as
well as sarcopenic obesity, compared to other ethnic groups and African populations
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demonstrated lower sarcopenia prevalence when compared to Caucasian populations [23, 30,
31].
Generally, Asian populations exhibit lower muscle mass, higher central adiposity, and
weaker grip strength and slower gait speed when evaluated for muscle performance [18]. In
addition to lower total muscle mass, the rate of decline in muscle strength with age appears more
rapid in Asian populations, notably in Asian females, compared to other ethnic groups [18].
Conversely, African Americans on average exhibit 5-8% greater muscle mass (and possibly 710% greater bone mineral density) compared to Caucasians [30]. In a study evaluating body
composition via DEXA scan, African women demonstrated both higher bone mineral mass as
well as greater skeletal muscle mass compared to Caucasian women [32].
Though some studies found higher rates of sarcopenia in other ethnic groups compared to
Asian populations, discrepancies may be due to lower Asian population cut-off points, given that
Asian populations exhibit lower overall muscle mass compared to other ethnic populations [11,
18]. In one study, average appendicular muscle mass among Asian subjects was around 15%
lower than non-Asian subjects, even after adjusting for height and age [29]. Therefore, lower
initial muscle mass may explain discrepancies in lower percentages for sarcopenia prevalence
and progression.
Given that the prevalence of sarcopenia is markedly higher in Asian groups compared to
other ethnic groups, we hypothesize that the association between sarcopenia and diabetes will be
greater or more pronounced compared to other ethnicities.
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WHAT IS DIABETES?
Diabetes mellitus is one of the most prevalent chronic and metabolic disease in the
United States, as well as globally [4]. The name is derived from the Greek “diabetes”—meaning
to siphon or pass through—and the Latin “mellitus” meaning sweet [33]. Type I diabetes and
Type II diabetes are the most common presentations of the condition; both involve difficulties in
regulating physiological blood glucose levels and either the absence or deficiency of insulin [33,
34]. Insulin is a peptide hormone that exerts a systemic effect and induces cells to take in glucose
via upregulation of glucose transporters inserted into the cell membrane. In diabetes, the absence
or deficiency of insulin prevents adequate cellular glucose uptake, leading to elevated blood
plasma glucose levels, a condition called hyperglycemia [33-35].
Presentation of Diabetes
Insulin resistance and hyperglycemia are defining conditions of diabetes that manifest in
characteristic physiological presentations and symptoms. In patients with diabetes, elevated
blood glucose levels oversaturate kidney nephron transporters that are responsible for
reabsorbing glucose. Consequently, excess glucose is excreted in the urine, producing “sweet”
(“mellitus”) urine [33]. Polyuria (increased frequency of urination), polydipsia (increased thirst),
weight loss, polyphagia (excessive appetite and eating), fatigue, blurred vision, numbness or
tingling in the extremities, and “fruity breath” from byproducts of increased ketosis are other
common symptoms [33-35]. Acanthosis nigricans—dark, hyperpigmented skin patches
commonly found on the back of the neck, axilla, and inguinal folds—may suggest underlying
diabetes [33].
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Diabetes often affects relevant vasculature and can lead to long-term comorbid
complications such as angiogenesis in the retina, blurred vision, potential loss of vision, renal
failure, amputation, and comorbid metabolic syndromes such as cardiovascular dysfunctions,
hypertension, and metabolic abnormalities in lipid and protein processing [6, 33-36].
Type I Diabetes
Type I diabetes most frequently appears in children and adolescents [37]. In Type I
diabetes, insulin-secreting beta cells in the pancreas are destroyed, leading to the absence or
underproduction of insulin, depending on the severity of the condition. Disruption of insulin
production is often the result of an autoimmune disorder in which the body attacks the beta cells
in the pancreatic islet [33, 34].
General markers indicating destructive autoimmune action on beta cells include
autoantibodies to islet cells, insulin, GAD65, and tyrosine phosphatases IA-2 and IA-2β [34].
Risk factors for Type I diabetes include family history, age (arises most often during childhood
or adolescence), and ethnicity (Type I diabetes is more prevalent in Caucasians compared to
African American and Hispanic ethnic groups in the US) [37].
Type II Diabetes
T2DM diabetes most frequently presents in adulthood (middle-aged and elderly) and
represents approximately 90% of those with diabetes [33, 34]. Many individuals with T2DM
diabetes are overweight, obese, or possess increased deposits of body fat in the abdominal region
[37]. T2DM diabetes involves impaired or deficient insulin action (insulin resistance). Insulin
resistance occurs when the body is unable to adequately respond to insulin: cells are unable to
effectively transport glucose intracellularly, leading to high systemic blood glucose levels
10

(hyperglycemia). In response to inadequate cellular glucose uptake, the pancreas attempts to
compensate by producing more insulin. Over time, insulin production capacities are exhausted
and insulin production declines [35].
The onset, presentation, and progression of T2DM diabetes is multifactorial and involves
a complex interplay of biological, genetic, and behavioral factors. Obesity, abdominal and
visceral fat storage, hypertension, dyslipidemia, low HDL, poor diet, physical inactivity, lifestyle
choices, and genetic predisposition are chief risk factors that contribute to T2DM. As with
sarcopenia, aging (45-years and older) places individuals at greater risk of T2DM. For women,
those with a history of gestational diabetes are also at greater risk for T2DM [6, 33-36].
Compared to Type I diabetes, T2DM demonstrates a stronger genetic predisposition and
heritability [33-35]. Numerous genes linked to diabetes susceptibility have been identified:
NOTCH2, WFS1, PPRAG, FTO, CDKAL1, IGF2BP2, JAZF1, HHEX, SLC30A8, and KCNJ11
[35].
In the case of diet as a contributory factor to T2DM, insulin resistance may surface as a
result of diets high in excess calories, saturated fats, refined sugars, and processed carbohydrates.
Such diets overload and exhaust metabolic pathways. Excess fat, especially around the
abdominal area, has been shown to trigger pro-inflammatory cytokines [2, 20].
In this paper, we will focus on the implications of T2DM and its relationship to
sarcopenia.
How is Diabetes Diagnosed?
Several lab tests are typically used to evaluate blood glucose levels and pertinent lab
values to detect and diagnose diabetes. Blood glucose levels can be evaluated following a period
11

of fasting, typically for at least 8 hours (fasting plasma glucose (FPG)) or in response to the
introduction of concentrated glucose (oral glucose tolerance test (OGTT)) [33-35]. Glycated
hemoglobin (HbA1c) is a type of hemoglobin that has been nonenzymatically linked to sugars; it
is often used as a measurement in determining diabetes risk or diagnosis [5].
According to the American Diabetes Association, diabetes can be diagnosed if one or
more of the following lab values exceed an established cutoff point: greater than 6.5% HbA1c, a
fasting plasma glucose level greater than 126 mg/dL upon an FPG test, a glucose concentration
greater than 200 mg/dL during an OGTT, or a random plasma glucose of 200 mg/mL in those
experiencing hyperglycemia or hyperglycemic crisis. Prediabetes is quantitatively defined as
having a fasting blood glucose of 100-125 mg/dL or an OGTT of 140-200 mg/dL. Screening is
recommended for adults 45 years old and older, regardless of current risk [7, 33-35].

Table 2. Diagnostic criteria for diabetes diagnosis according to guidelines established by the American
Diabetes Association (ADA).

American Diabetes Association (ADA) Criteria for Diabetes Diagnosis
1. HbA1c ≥ 6.5% using a laboratory test that is certified by the National Glycohemoglobin
Standardization Program (NGSP) and standardized by the Diabetes Control and Complications
Trial (DCCT) assay.
2. Fasting Plasma Glucose (FPG) ≥ 126 mg/dl following a fast of at least 8 hours.
3. 2-hour plasma glucose ≥ 200 mg/dl during at OGTT performed in adherence to standards
set forth by the World Health Organization (WHO) with a glucose load of 75 g anhydrous
glucose dissolved in water.
4. A random plasma glucose ≥ 200 mg/dl in an individual with persistent hyperglycemia or
hyperglycemic crisis.
Diabetes is diagnosed if at least one of the criteria above are met. Lab results should be repeated to eliminate
potential errors. If two diagnostic criteria are in conflict, the criterion above the threshold should be repeated to
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determine diabetes diagnosis. Adapted from “Diagnosis and Classification of Diabetes Mellitus” by the American
Diabetes Association, 2010. Copyright 2010 by the American Diabetes Association. [34]

Current Therapeutic Approaches to Diabetes
Patient awareness, education, and engagement is a critical step in addressing therapeutic
approaches for diabetes. Dietary modifications include caloric restriction, monitoring
carbohydrate intake, reducing intake of foods high in processed sugar and fat, and regularly
incorporating fruits, vegetables, vitamins, and fiber into the diet [3]. Regular exercise (3-5 times
a week, for at least 45-minute sessions) is encouraged. Lifestyle interventions may also involve
patient monitoring of blood glucose levels: maintenance of blood glucose values around 90-130
mg/dL with an HbA1c of less than 7% is ideal. Though lifestyle interventions, weight reduction,
and pharmacological therapies may improve patient outcomes, full functional restoration to one’s
original state is rare [33].
In addition to behavioral and dietary changes, insulin injections may be administered,
especially in those with Type I diabetes (insulin-dependent diabetes). Metformin may be
prescribed to lower blood plasma glucose levels postprandially and at baseline [33]. Other drugs
such as sulfonylureas, thiazolidinediones, sodium-glucose transport protein 2 inhibitors
(SGLT2i), dipeptidyl peptidase-4 inhibitors (DPP-4i), and glucagon-like peptide-1 receptor
agonists (GLP-1 RAs) may be prescribed to lower blood glucose levels and control
hyperglycemia [1]. Bariatric surgery may be recommended in those who are morbidly obese
[33].

13

Frequent evaluation is recommended due to potential macro and microvascular
complications and elevated risk of hypertension, dyslipidemias, nephropathies, retinopathies, and
neuropathies [33-35].
Diabetes Prevalence and Trends
Since its first recording around 300 years ago in Egypt, diabetes prevalence has
consistently increased. Longer lifespans have facilitated an increasingly aging population, and
global marketplaces have given rise to Westernized diets and sedentary behavioral changes, both
of which have contributed substantially to the accelerating diabetes epidemic. Moreover, obesity
contributes to nearly 55% cases of T2DM [35]. By 2040, the number of individuals with diabetes
is expected to increase from 415 million (in 2021) to 642 million [33]. Increasing rates of child
obesity have given rise to increased incidences of T2DM in children and young adults [4, 35].
In the United States, diabetes represents the 7th leading cause of death [33]. In 2018,
10.5% of the adult US population (34.2 million individuals) had diabetes; 7.3 million (21.3% of
those with diabetes) were undiagnosed. Within the US, 26.8% of persons aged 65 and older have
diabetes. In addition, approximately 1.5 million new cases of diabetes are diagnosed each year
[4].
Diabetes exhibits interesting trends among different ethnic groups. African Americans,
Hispanics, Asian Americans, Native Americans, Pacific Islanders, and Pima Indians have a
higher prevalence of diabetes—2-6 times higher—when compared with Caucasians in the U.S.
[33, 38]. Compared to Caucasians, the percentage of those with diabetes among other ethnic
groups is higher: 7.5% of non-Hispanic whites, 9.2% of Asian Americans, 11.7% of nonHispanic blacks, 12.5% of Hispanics, and 14.7% of American Indians and Alaskan Natives.
14

Diabetes rates remain particularly high for Native Indian groups. Among Asian Americans,
Asian Indians had the highest rate of diabetes; among Hispanic Americans, Mexican Americans
had the highest diabetes rate [4]. Interestingly, Asian American individuals with diabetes
demonstrated lower BMI values, as well as higher body fat—particularly visceral fat—
compared with other ethnic groups [39, 40].
Globally, the countries with the highest diabetes prevalence in 2019 were Mauritius,
Tuvalu, Sudan, Kiribati, and the Marshall Islands, with 22%, 22.1%, 22.1%, 22.5%, and 30.5%
of the population aged 20 to 79, respectively [41]. Of these top 5 countries, 4 are island nations:
3 Pacific islands and 1 island off the coast of Africa.
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Relationship Between Sarcopenia and Diabetes
Several papers have established a reciprocal relationship between diabetes and
sarcopenia, some citing a sarcopenia prevalence two or three times higher in diabetic patients
compared to healthy controls, and vice versa [1-3, 5-12]. The risk of developing sarcopenia for
those with T2DM is significantly higher compared to euglycemic controls, and the risk of
sarcopenic patients developing diabetes is significantly higher than nonsarcopenic patients.
Accelerated loss of muscle strength and mass has been identified in individuals with T2DM [11].
Overall, sarcopenia has been identified as both a causative factor, as well as a consequence, of
T2DM.
Factors that Contribute to the Relationship Between Sarcopenia and Diabetes
Several factors have been implicated in contributing to the sarcopenia-diabetes relationship:
insulin resistance, altered metabolism, advanced age, increased adiposity, inflammation,
oxidative stress, advanced glycation end-products (AGEs), vascular complications, muscular
atrophy, reduced muscle quality, and decreased muscle function [1-3, 7, 11].
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Figure 1. Graphical representation of the reciprocal relationship between sarcopenia and diabetes. Graphical
representation of the reciprocal relationship between sarcopenia and diabetes. Aging, decreased production of
anabolic hormones, low caloric intake, low protein intake, and osteoporosis are risk factors for sarcopenia.
Sarcopenia may result in increased risk of fracture, falls, accidents, and hospitalization, as well as decreased range of
motion, disability, autonomy, and increased bedrest. Insulin resistance, chronic hyperglycemia, excess caloric
intake, a diet high in processed sugars, carbohydrates, and saturated fats, overweight or obese BMI classification,
and increased central or visceral adiposity are risk factors for T2DM. Aging, genetics, mitochondrial dysfunction,
oxidative stress, AGE accumulation, diet and nutrition quality, sedentary behavior, lack of physical activity, and
stress are contributing factors to both sarcopenia and diabetes. The relationship between sarcopenia and diabetes
may result in sarcopenic obesity, metabolic dysfunction and dysregulation, and a vicious cycle in which factors
influence and are influenced by other factors in the metabolic network. Sarcopenia and diabetes have contributed to
increasing healthcare costs (increased hospitalization, medication, nonpharmacological treatments, and other
associated patient services), decreased quality of life, and increased morbidity and mortality.
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Insulin Resistance
Insulin resistance is one of the key presentations of diabetes. Body compositions with
lower muscle mass and higher fat mass have been associated with higher insulin resistance [5, 9,
20]. Insulin exerts anabolic actions in the body: it promotes protein synthesis and musclebuilding, but impairment in insulin signaling and response contributes to decreased protein
synthesis and consequent elevated protein breakdown—to compensate for intracellular glucose
starvation—and overall reduced muscle mass [11, 12]. Muscle tissues that are unresponsive to
insulin are prevented from obtaining adequate glucose, which may contribute to myocyte
dysfunction and related myopathies, as well as impairing existing muscle and decreasing muscle
synthesis and, consequently, muscle mass. Those with T2DM are at greater risk for losing over
5% of total lean, fat-free muscle mass over a 5-year period [2]. Further, lower levels of anabolic
hormones, such as testosterone, have been found in patients with diabetes [5].
Elevated insulin resistance and consequent hyperglycemia has been linked to higher fat
mass as well as lower muscle mass. In a study by Ogama et al., no relationship between
hypoglycemia and sarcopenia was found, while hyperglycemia has been implicated in
contributing to mitochondrial dysfunction and peripheral neuropathies [5]. In addition, in a study
by Ai et al., patients administered metformin (a drug primarily used to control symptoms of
diabetes and hyperglycemia) were not at a comparable risk to develop sarcopenia compared to
patients with chronic hyperglycemia who had not received metformin [9].
Insulin resistance and chronic hyperglycemia presents with a plethora of comorbidities:
dyslipidemia, hypertension, cardiovascular disease, vascular pathologies, (retinopathy,
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neuropathy, nephropathies) and consequent complications (stroke, peripheral artery disease,
heart attack, coronary heart disease) [6, 33-36].
Altered Metabolism
Chronic hyperglycemia and insulin resistance systemically alters metabolism. Glucose is
the body’s primary energy source, and disturbance of this pathway has downstream effects on
lipid and protein processing. Maladaptive metabolic strategies produce a vicious, cyclic state in
which one condition affects or is affected by the other. For example, altered cellular glucose
uptake and insulin resistance forces the body to utilize alternative energy sources such as fat,
and, in severe cases, protein, which significantly impairs muscle synthesis and function. In
extreme cases, ketoacidosis—a severe complication in diabetic patients—occurs when acidic
ketone body byproducts accumulate in the body as a metabolic consequence of increased fat
metabolism when starved of glucose. These acidic ketone bodies interfere with blood pH balance
and, if not treated, may result in fatal diabetic coma [33].
In another instance, decreased muscle mass, as in sarcopenia, reduces the number of
tissues that can take in and process glucose. This may aggravate insulin resistance, disturb
mitochondrial function, increase oxidative stress, or facilitate increased adiposity, which can
secrete pro-inflammatory cytokines.
The systemic impact of altered metabolism is evident in the sheer number of metabolic
comorbidities that generally coincide or are often observed together. For instance, diabetes is
often comorbid with dyslipidemias and vasculopathies. Sarcopenia can be comorbid with
osteoporosis and, similar to diabetes, dyslipidemias.
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Hyperglycemia is not the only factor associated with sarcopenic risk: fluctuations in
glucose levels have also been shown to be correlated with decreased muscle mass, grip strength,
and gait speed [5].
Advanced Age
As individuals age, progressive changes and declines in physiological functions are
expected. Notably, elderly patients with diabetes have lower muscle mass than non-diabetic
elderly individuals [2, 5].
As individuals age, declines in testosterone, estrogen, adrenocorticotrophic hormone
(ACTH), and growth hormone alter metabolism and homeostasis [9]. Hormonal disturbances
have systemic effects on metabolism and may affect insulin secretion and regulation, lipid
processing, and skeletal muscle organization and strength.
As aging progresses, individuals are at a higher risk for vitamin D deficiency. Vitamin D
is an important regulator of calcium and phosphorus concentrations in the body. It promotes
calcium and phosphorus reabsorption, thereby playing a role in bone mineralization and
turnover. In older individuals, skeletal muscle receptors for vitamin D may be downregulated,
decreasing its action in the body, which may result in lower bone mass and bone frailty [9].
Osteoporosis, a condition prevalent in the elderly population, involves decreased bone
mass, deterioration of bone structure, and bone weakness and frailty. 1 in 3 females above age 50
and 1 in 5 males will experience osteoporotic fractures. Bone and muscle health are closely
associated, and osteoporosis is a significant predisposing and contributive factor for sarcopenia
development [42].
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Older individuals are more susceptible to chronic, comorbid diseases. In a study by
Ogama et al., diabetic patients who also had cognitive impairment exhibited higher rates of
sarcopenia compared to healthy controls [5]. Additionally, peripheral neuropathies can decrease
range of motion and reduce engagement in physical activity in elderly patients [3, 7, 12].
Compared to controls, older patients comorbid with T2DM and sarcopenia exhibited higher
mortality rates and risk following hospital discharge [8]. Weakening of muscle and bone in older
age puts elderly patients at greater risk for accidents, particularly falls, leading to higher
mortality [7-9, 13, 15, 16].
Older adults are at greater risk for malnourishment (a lack of adequate nutrients or
nutritional imbalances that can occur in individuals of low, normal, or high BMIs) and
undernourishment (a lack of adequate nutrition or calories that is often seen in underweight
individuals) [43]. Inadequate nutrition, when combined with sedentary behavior, increases
susceptibility for muscle wasting, which predisposes patients to both sarcopenia and diabetes.
Obesity
T2DM is most prevalent in those with a higher BMI and waist circumference [6]. White
adipose tissue (WAT), and visceral adipose tissue (VAT) in particular, are known secretors of
inflammatory molecules that contribute to a chronic, low-grade cytokine storm that can alter
metabolism and glycemic control [2, 20].
Sarcopenic obesity illustrates the exhaustive cycle of inflammation, insulin resistance,
and metabolic dysfunction that can contribute to the sarcopenia-diabetes relationship. Excess
adipose tissue secretes cytokines, triggering a chronic state of low-grade, systemic inflammation
which induces a cascade of metabolic disturbances such as insulin resistance, dyslipidemias, and
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oxidative stress. Disrupted glucose metabolism and subsequent cellular glucose starvation
dissuades protein synthesis, producing lower muscle mass as well as decreased muscle strength
and function [7].
Inflammation
Molecular markers associated with inflammation have been identified and linked to
insulin resistance and increased adiposity. Persistent, low-grade chronic inflammation has also
been linked to aging, as well as the age-influenced pathogenic processes associated with aging.
Muscular inflammation, from both primary disease pathogenesis, as well as secondary causes,
may produce inflammation-promoting cytokines that further contribute to sarcopenia, in addition
to disturbing metabolic pathways. Elevated inflammatory markers have been found in those with
T2DM diabetes in both obese and non-obese individuals. Visceral adipose tissue secretes IL6
and TNF, cytokines that are instrumental to the inflammatory pathway [1, 2, 5, 7, 11, 20, 26].
Increased central and visceral adiposity combined with low muscle mass exposes vital metabolic
organs to an environment of persistent, low-grade inflammation.
Advanced Glycation End Products (AGEs)
AGE accumulation has been shown to impair muscle function and produce muscle
atrophy, though the exact mechanism is not yet known [11]. Accumulation of AGEs may
contribute to crosslinking, stiffness, and degradation of muscle proteins [1, 11]. Elderly females
with heightened AGEs demonstrated poorer handgrip strength, as well as slower gait speed [11].
Moreover, elevated blood glucose shunts excess glucose to the polyol pathway, which produces
metabolites that may reduce antioxidant capacities and promote oxidative stress [1].
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Mitochondrial Dysfunction
Mitochondrial DNA mutations increase as aging progresses [2]. Mutations in
mitochondrial genes affect gene expression and mitochondrial function, potentially stimulating
apoptotic pathways. Mitochondrial mutations accrued over time may increase the permeability of
the mitochondrial membrane, permitting spillage of contents that can initiate apoptotic signaling
cascades. Alternatively, excess lipids may encroach in the mitochondria and produce reactive
oxygen species that produce insulin-signaling-inhibiting intermediates [11]. Mitochondrial
dysfunctions are physiologically manifest as muscle weakness, frailty, and atrophy.
Oxidative Stress
As individuals age, oxidative stress increases and antioxidant capacity decreases [2]. The
systemic metabolic changes that occur in T2DM—insulin resistance, disturbed lipid and protein
processing, decreased anabolic capacity, metabolite accumulation, and mitochondrial
dysfunction—also contribute to increased oxidative stress, dysregulation of metabolic
homeostasis, and associated myopathies [1, 2, 7, 11]. Buildup and decreased clearance of free
radicals such as reactive oxygen species—as in metabolically disruptive pathologies like T2DM
and sarcopenia—damage tissues and their corresponding functions [9]. In the case of muscle,
increased oxidative stress can lead to progressive weakening, decreased synthesis and
regeneration, and decreased ability to take up and utilize glucose—all of which contribute to
sarcopenia, diabetes, and the sarcopenia-diabetes relationship [2, 11]. Notably, as
aforementioned, elderly patients exhibit increased mutations in mitochondrial DNA compared to
younger adults [2]. Mitochondrial mutations may present with altered functioning, decreased
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oxidative capacity, and, on a systemic level, overall decreased muscle strength, function, and
performance.
Reduced Muscle Quality and Myopathy
A study by Mesinovic et al. found that waist circumference is negatively associated with
the strength, performance, and quality of muscle in both overweight and obese elderly
individuals [2]. Reduced muscle mass, as characteristic of sarcopenia, decreases tissues which
otherwise would serve as insulin targets, facilitating hyperglycemia and the development of
insulin resistance. In older diabetic adults with cognitive impairment, fluctuations in blood
glucose were associated with indicators of sarcopenia: lower muscle mass and strength and
slower walking speeds. Impairment in muscle performance and function in those with T2DM
may increase sedentation and create a self-perpetuating cycle in which, according to Mesinovic,
“functional impairments lead to metabolic impairments, and vice versa.” [2]
Lifestyle: Exercise
One of the difficulties with evaluating and treating sarcopenia, diabetes, or both, is the
cyclical and complex nature of the pathological relationship and how this relationship is
perpetrated through behavioral and environmental influences. In an increasingly technological
age, many jobs have shifted from manual labor and consistent physical activity to sedentary,
office-oriented occupations. Lack of adequate movement and exercise—as exhibited by many
twenty-first century sedentary lifestyles—puts individuals at an increased risk of gaining weight
and losing muscle mass. Excess weight and increased adiposity—and its downstream milieu of
metabolic derangements—is a prominent contributory factor in diabetes, particularly for
individuals whose adiposity concentrates in the abdominal and visceral regions, as has been
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previously observed in Asian populations of various ethnicities [44]. Lack of exercise also
contributes to muscle wasting and atrophy, as observed in presarcopenia and sarcopenia. Elderly
individuals represent a population predominantly restricted to sedentary lifestyles as the result of
underlying conditions that decrease range of motion, prevent mobility, or intentionally
discourage regular physical activity in efforts to reduce fracture or accident risk [9, 16].
Additionally, sedentation further exacerbates the sarcopenia-diabetes relationship by increasing
the risk of sarcopenic obesity in the event of increased fat mass concurrent with maintained or
decreasing muscle mass. Regular exercise, with an emphasis on resistance training (especially in
elderly individuals), has been shown to reverse and improve sarcopenia and diabetes outcomes
[1, 17, 20].
Lifestyle: Diet
Elderly individuals often experience decreased appetite. Deficient caloric and protein
intake results in weight loss, which also aggravates muscle loss and muscle wasting when
combined with increased bedrest and decreased physical activity [45, 46].
In contrast, excess caloric, carbohydrate, protein, and fat intake can overwhelm, exhaust,
and ultimately alter metabolic systems. Many modern-day diets have shifted from predominantly
fresh, plant-based, traditional foods to highly processed meals of larger portions, excess sugar,
surplus and empty calories, and decreased fiber, whole-grains, vegetables, and fruit. Many
modern-day staples such as baked goods, processed breads, and snacks contain high
carbohydrate content. Many of these carbohydrates have high glycemic indexes that can spike
blood sugar levels and contribute to hyperglycemia and the development of insulin resistance
[47].
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In both cases, deficient or excessive dietary intakes may contribute to metabolic
disturbances that incite sarcopenia, diabetes, or an interplay between sarcopenia and diabetes.
Of important note, diets vary greatly among different ethnic groups and regions. For
example, Hispanic cuisine contains an assortment of tomatoes, beans, and peppers, which may
have anti-inflammatory benefits. Asian cuisine features many vegetables, rice, and broth-based
cuisine, but traditional fare does not include high amounts of dairy, which is an important source
of calcium. Starchy tubers (cassava, yams), plantains, and okra are often incorporated into
traditional African cuisine. Though many modern-day diets are shifting from traditional to more
Western-styled fare, variations in ethnic and regional cuisine may contribute to anthropomorphic
differences, decreased percent muscle mass, increased adipose distribution, and increased risk of
sarcopenia and diabetes.

Significance
Sarcopenia and diabetes represent two conditions that have become increasingly
concerning in the modern world: aging and obesity. It has previously been established that
sarcopenia and diabetes may take on a reciprocal relationship in which the symptoms of one
condition can influence or be influenced by the other.
Advances in healthcare, sanitation, and public health increased human lifespans over the
past centuries. At the same time, birth rates in developed countries have drastically declined as a
result of increased costs of living, the movement from agricultural to urban life, and an emphasis
on education and office-oriented occupations. Longer lifespans, combined with a shrinking
young (children, adolescents, young adults) age group, have given rise to characteristic, inverted
population pyramids in which a narrowing middle age group must support a growing elderly
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population. As individuals age, muscle mass, quality, and strength decline while fat mass
increases. Sarcopenia is a natural result of aging but may be accelerated by environmental and
behavioral factors. Amidst a progressively aging population, sarcopenia represents, on a large
scale, a burgeoning healthcare cost (increased hospitalization, medication, and associated
treatments, especially among older individuals), and, on a personal level, a source of decreased
quality of life (decreased range of motion, increased bedrest, increased risk of fall, fracture, or
accidents, and limited autonomy).
Furthermore, globalization and increasing global interconnectedness in a technological
landscape have created a notable shift in lifestyles and diets. Western trends have diffused to far
reaches of the globe (Westernization), influencing, and in some cases reshaping, traditional
lifestyles. Western diets often consist of processed foods with high amounts of sugar, refined
carbohydrates, and saturated fats. Fast-food chains—as well as trademarked pre-packaged snacks
and beverages—that have spread across the world provide menus that are convenient, but often
higher in calories and lacking adequate nutrition (“empty calories”). Additionally, a technology
and service-oriented global community with an emphasis on corporate and monetary success,
efficiency, and standardization, has shifted modern lifestyles from active to predominantly
sedentary. Altered diets, sedentary lifestyles, and stress have significantly contributed to the
growing obesity epidemic. T2DM is a condition that affects 415 million individuals
worldwide—roughly 6% of the current world population [33]. Overweight and obesity are two
substantial predisposing factors for T2DM. Along with T2DM, obesity gives rise to other
comorbidities, chiefly, heart disease, the number one cause of death in the United States [48].
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Over the past century, healthcare costs for obesity-related comorbidities and T2DM have rapidly
risen.
Sarcopenic obesity illustrates a condition where both aging and obesity coexist, interact,
and reciprocally exacerbate symptoms. Excess fat secretes a milieu of inflammatory cytokines
that alter metabolic pathways and obstruct protein synthesis necessary for maintenance of muscle
tissue. Decreased muscle mass worsens insulin resistance and contributes to an adipose-mediated
state of low-grade inflammation. Altered metabolic pathways create an avenue for a collection of
comorbidities: hyperlipidemia, dyslipidemia, heart disease, osteoporosis, micro and
macrovascular complications, and renal dysfunction.
Together, sarcopenia and diabetes contribute to declining muscle mass, strength, and
quality as well as insulin resistance, inflammation, and systemic metabolic disturbances. There is
a higher prevalence of sarcopenia among individuals with T2DM, as well as a higher prevalence
of T2DM among those with sarcopenia. The relatively recent recognition of sarcopenia as a
distinct disease, has put greater emphasis and attention on prophylactic screening starting in
middle-aged adults, when the onset of sarcopenia most commonly occurs. Like sarcopenia,
diabetes often arises in middle-age and progresses as individuals age. Early screening and
identification are key to combating reversible aspects of sarcopenia and diabetes through lifestyle
modifications, improved nutrition, and regular physical activity.
This project aims to analyze whether the relationship between sarcopenia and diabetes
differs among different ethnic groups. Advancements in genetic and molecular technology have
fostered increasing interest in personalized medicine. Understanding the variations of disease
processes across unique individuals may help to develop more efficient treatment options,
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medications, and associated therapies to better suit the individual and improve patient outcomes.
Understanding how factors such as ethnic group and family history play a role in disease
presentation, severity, and risk may provide further insight into developing treatment options that
are more specific, tailored, and effective compared to more general, homogeneous treatment
programs.
Patient outcomes for both sarcopenia and diabetes are influenced by potentially reversible
factors, if detected early and met with the appropriate lifestyle modifications. Determining the
strength of the sarcopenia-diabetes relationship for different ethnic groups may inform
development of standardized procedures to detect high-risk individuals. The coexistence and
interaction of sarcopenia and diabetes has systemic consequences that affect numerous metabolic
pathways and may increase the risk of various comorbidities. Early identification is important in
determining the course of treatment, as well as patient outcomes. Implementing timely patient
awareness and education, as well as subsequent preventative, prophylactic lifestyle modifications
may greatly reduce the onset of sarcopenia or diabetes or ameliorate symptoms.
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STATISTICAL ANALYSIS BACKGROUND
ANOVA
In this project, a one-way analysis of variance (ANOVA) test will be used. ANOVA tests
are designed to determine if a statistically significant difference exists between the means of
three or more groups. A one-way ANOVA examines one independent variable, while a two-way
ANOVA examines two or more independent variables (multiple levels).
In addition to ANOVA, the Student’s t-test can determine if a difference in means exists.
However, the t-test can only determine the difference between two groups. If one wishes to
analyze multiple groups, one will need to perform multiple repetitions of t-tests on different twogroup combinations. Using ANOVA reduces the need to perform multiple t-tests, as it produces
a single, representative F-statistic and p-value. Furthermore, performing multiple t-tests runs the
risk of producing a Type I error, which occurs when one incorrectly rejects the null hypothesis
and states that a statistically significant difference exists when one does not.
Though ANOVA can determine if a difference between group means exists, it cannot
determine which groups differ from each other. Given a significant difference is obtained, post
hoc tests will be performed to search for further differences between groups.
This meta-analysis will use JASP to perform ANOVA, but the following steps can be
performed if done by hand:
1. State the assumptions and the null and alternative hypotheses.
The following assumptions are made when conducting ANOVA:
(1) All samples are independent of each other and randomly selected.
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(2) All samples follow a normal distribution or have a sample size that is greater than or
equal to 30.
(3) Population standard deviations or variances are assumed to be equal.
The null hypothesis (H0) states that no statistically significant difference exists between
the group means (n, where n = one of the given groups). The alternative hypothesis (Ha) states
that a statistically significant difference exists between the group means. Taking c = Caucasian,
af = African, h = Hispanic, and as = Asian, the following may be written:
H0: c = af = h = as
Ha: c  af  h  as
2. Calculate the group means.
This is done by taking the average (adding up all the values in a given group, then
dividing by the number of values in that group) for each group.
𝑥̅ =

Σx
𝑛

OR

𝑠𝑢𝑚 𝑜𝑓 𝑣𝑎𝑙𝑢𝑒𝑠 𝑓𝑟𝑜𝑚 𝑎 𝑔𝑖𝑣𝑒𝑛 𝑔𝑟𝑜𝑢𝑝

group mean = 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑣𝑎𝑙𝑢𝑒𝑠 𝑓𝑟𝑜𝑚 𝑎 𝑔𝑖𝑣𝑒𝑛 𝑔𝑟𝑜𝑢𝑝

3. Calculate the overall mean.
This is done by taking the average (adding up all the values from all groups, then
dividing by the total number of values) of all the values in the study.
𝑥̅ =

Σx
𝑛

OR

𝑠𝑢𝑚 𝑜𝑓 𝑣𝑎𝑙𝑢𝑒𝑠 𝑓𝑟𝑜𝑚 𝑎𝑙𝑙 𝑔𝑟𝑜𝑢𝑝𝑠

overall mean = 𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑣𝑎𝑙𝑢𝑒𝑠 𝑓𝑟𝑜𝑚 𝑎𝑙𝑙 𝑔𝑟𝑜𝑢𝑝𝑠

4. Calculate the “within group” variation (SSwithin).
The SSwithin is the sum of squares of variation within each sample group. This is a
measure of the variation due to error or chance within each group. To find the SSwithin, the sum of
the differences between a given group value and the group mean is taken. Taking q as the value
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of the qth observation in a given group, and r as the mean of the given group, the following
formula may be used:
Σ(Xq – Xr)2
5. Calculate the “between group” variation (SSbetween).
The SSbetween is the sum of squares of variation between different sample groups in a
study and can be viewed as a measure of between-sample variation due to chance or error. To
obtain the SSbetween, the sum of the squares of the differences of each group and the overall mean
is calculated. Given Yr is the mean of a given group r and Y is the overall mean, the following
formula may be used:
Σ n(Yr – Y)2
6. Determine the degrees of freedom.
In general, the degrees of freedom are calculated by subtracting 1 from the number of
values in a sample.
df = (# of values) – 1
ANOVA tests have two degrees of freedom: the dfwithin and the dfbetween.
The dfwithin is obtained by subtracting the number of groups from the total sample size.
dfwithin = (total sample size) – (# of groups)
The dfbetween is obtained by subtracting 1 from the number of groups in the study.
dfbetween = (# groups) – 1
7. Determine the Within and Between Mean Squares (MSwithin and MSbetween).
The MSwithin is obtained by dividing the SSwithin by the dfwithin.
𝑆𝑆 𝑤𝑖𝑡ℎ𝑖𝑛

MSwithin = 𝑑𝑓 𝑤𝑖𝑡ℎ𝑖𝑛
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The MSbetween is obtained by dividing the SSbetween by the dfbetween.
𝑆𝑆 𝑏𝑒𝑡𝑤𝑒𝑒𝑛

MSbetween = 𝑑𝑓 𝑏𝑒𝑡𝑤𝑒𝑒𝑛
8. Determine the F statistic.
The F statistic is a ratio of the variation between groups to the variation within groups. To obtain
the F statistic, the MSbetween is divided by the MSwithin.
F-statistic =

𝑀𝑆 𝑏𝑒𝑡𝑤𝑒𝑒𝑛
𝑀𝑆 𝑤𝑖𝑡ℎ𝑖𝑛

9. Use an F distribution table and the calculated - statistic to determine the p-value and statistical
significance.
For ANOVA, the F distribution table is used to determine the p-value for a given Fstatistic. The F distribution differs from the normal distribution. It is not symmetrical and is
instead skewed right; the F distribution takes on distinct curves for different degrees of freedom.
The F distribution contains different critical values for each given set of degrees of freedom.
Based on the given set of dfs, the calculated F statistic is compared with the F critical
value from the F distribution table. A result is considered statistically significant if the calculated
F-statistic is greater than the F critical value; if this is the case, the null hypothesis is rejected in
favor of the alternative hypothesis.
A large F statistic implies a larger MSbetween (numerator) and a smaller MSwithin
(denominator); this suggests there is low in-group variation and greater between-group variation.
Additionally, a larger F-statistic results in less area to the right of the F distribution curve,
yielding a lower p-value. Provided an alpha significance level of 0.05, less area to the right of the
curve is a consequence of a lower p-value, which, if less than the alpha level of 0.05, produces a
statistically significant result. If the F statistic is less than the F critical value, the result is not
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statistically significant, and one fails to reject the null hypothesis. A low F statistic suggests there
is greater variation within the groups (larger denominator) and less variation between groups
(smaller numerator). Furthermore, there is greater area to the left of the curve, resulting in a pvalue that exceeds the alpha significance level of 0.05. [49-51]
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OBJECTIVES
The reciprocal relationship between sarcopenia and diabetes has been confirmed, but to
the best of our knowledge, no studies have analyzed how ethnicity may affect or modify this
relationship. The objective of this project is to perform a meta-analysis to further explore the
relationship between sarcopenia and diabetes, to determine whether a significant difference in
the strength of the relationship exists among different ethnic groups, and to suggest future
research directions and perspectives based on the given results. The aims of this project are as
follows:
Aim 1: Study Identification and Data Collection
•

To achieve this aim, a systematic literature search will be performed using PubMed.

•

Specific search keyword combinations using Medical Subject Headings (MeSH) terms
will be developed to better narrow the search. A specific search string will be developed
and employed for each ethnic group.

•

The following ethnic groups will be analyzed in this meta-analysis: African, Hispanic,
Caucasian, and Asian.

Aim 2: Statistical Analysis of Collected Studies
•

A statistical analysis of the collected studies will be performed using the data analysis
program JASP, a free, open-source software available via the courtesy of the University
of Amsterdam, Department of Psychology and Psychological Methods Unit.

•

ANOVA will be performed on data from the collected studies.

•

Provided a difference is detected, post-hoc paired t-tests will be performed to determine if
differences exist between different ethnic groups.
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Aim 3: To Analyze the Differences Among Ethnic Groups Regarding the Strength of the
Relationship Between Sarcopenia and Diabetes
•

Data from Aim 2 will be used to reach a conclusion regarding whether a significant
difference exists regarding the strength of the sarcopenia-diabetes relationship between
different ethnic groups.

Aim 4: To Propose and Discuss Possible Reasons for Ethnic-Specific Discrepancies (if
shown to exist)
•

Results from Aim 3 will be used to propose and discuss possible reasons for ethnicspecific differences (if differences are shown to exist).

•

Personalized medicine and early detection of high-risk individuals will be discussed in
the context of relevant findings.

•

If no statistically significant difference is shown to exist, reasons for the absence of this
given measure will be explored.
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METHODS
Data for this meta-analysis will be obtained from searching the online, international
database PubMed. Specific combinations of search strings for each ethnic group were developed
using Boolean operators and MeSH terms to further narrow and specify search results. The
following are the combinations of search terms used:
African
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Hispanic
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Caucasian

39

Asian

The above combinations of search terms produced a total of 333 results: 5 studies for the
African group; 12 studies for the Hispanic group; 89 results for the Caucasian group; and 227
studies for the Asian group.
The resulting studies were screened for data on the prevalence of sarcopenia and
diabetes; studies that did not include data on participants with concurrent sarcopenia and diabetes
were excluded from this study. Studies with the following characteristics were excluded: not
written in English, published more than 10 years ago (before 2011), included individuals under
40

18 (child and adolescent studies), conducted on only one gender, and conducted on animals.
Individual study exclusion criteria were evaluated such that participants included in this metaanalysis were considered relatively healthy without outstanding, potentially confounding health
conditions (cognitive impairment, recent invasive surgeries, ambulatory difficulties, etc.).
Studies conducted in the United States were not included in the meta-analysis to reduce
difficulties associated with ethnic heterogeneity compared to more homogenous study
populations found in countries like Japan and Korea. Additionally, reviews, meta-analyses,
individual case studies, and letters were excluded.
After removing duplicates and conducting initial screening, 38 studies were selected for
in-depth evaluation and 26 studies were selected for inclusion in the meta-analysis [6, 8, 52-75].
22 studies had a cross-sectional design; 3 studies had mixed study designs (a combination of
cross-sectional and cohort); 1 study had a cohort design. There were 5 studies for the Hispanic
group [6, 8, 55-57], 3 studies for the Caucasian group [52-54], and 18 studies for the Asian group
[58-75]. Due to lack of eligible study data, the African group was not able to be included in the
final analysis.
The following information was collected from each study: first author, publication date,
type of study performed, diagnostic method for diabetes diagnosis, definition of sarcopenia used,
number of participants in study, mean age of participants, subject sex ratio (via percentage of
male participants), number of participants with T2DM, number of participants with sarcopenia,
number of participants with T2DM and sarcopenia, average BMI of participants, and a brief
summary of key results and conclusions obtained.
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Figure 2. Preferred Reporting Items for Systematic Reviews (PRISMA) for identification of studies via
databases. Chart adapted from Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al.
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi:
10.1136/bmj.n71. [76] Licensed under the Creative Commons Attribution License.
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JASP open-source software will be used to analyze data collected from selected articles.
ANOVA will be performed to obtain an F-statistic and p-statistic to determine significance, as
well as an 2 value to conceptualize effect size. The mean value that will be compared through
ANOVA will consist of the group means of the following measurement:
𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙𝑠 𝑤𝑖𝑡ℎ 𝑏𝑜𝑡ℎ 𝑆𝐶+𝑇2𝐷𝑀

value for study x = 𝑡𝑜𝑡𝑎𝑙 𝑠𝑡𝑢𝑑𝑦 𝑖𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙𝑠 𝑤𝑖𝑡ℎ 𝑇2𝐷𝑀
In this project, this value will serve as a numerical measure of the strength of the
relationship between sarcopenia and diabetes. The above value will be calculated for each of the
studies and the values for each study within an ethnic group will be averaged to produce the
group mean. Moreover, the number of individuals with both sarcopenia and T2DM will be
divided by the total number of individuals with T2DM. Using the SSwithin, SSbetween, MSwithin, and
MSbetween values from the ANOVA calculations, the difference in means will be compared within
groups, as well as between groups to determine if a statistically significant difference in means
exists among different ethnic groups.
For this meta-analysis, the null and alternative hypotheses will be as follows:
H0: no difference in means exists among the Hispanic, Caucasian, and Asian groups
Ha: a difference in means exists among the Hispanic, Caucasian, and Asian groups
Results will be considered statistically significant at an alpha level of p < 0.05.
A conclusion will be reached based on the results of the statistical analysis. Reasons for
discrepancies, potential rationale for observed differences, and suggestions for future research
directions will be given. Additionally, given a significant difference exists, this study will
incorporate post hoc tests to determine if any notable differences exist between two ethnic
groups.
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Timeline
August 2021 – December 2021
•

Aims 1 and 2

January 2022 – April 2022
•

Aims 3 and 4
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RESULTS
After searching and screening PubMed, 26 studies out of the initial 333 were selected for
statistical analysis. After removal of duplicates, of the 322 studies screened for eligibility, reports
were excluded for the following reasons: (i) did not contain relevant data (unrelated topic,
extraneous data, etc.), (ii) contained study individuals with outstanding, confounding health
conditions, (iii) provided data on either sarcopenia or diabetes, but not on their co-occurrence,
(iv) conducted only one gender, (v) child study or study including children (persons younger
than 18 years of age), (vi) animal studies, (vii) did not include breakdown for each ethnicity,
(viii) study not written in English, and (IX) case study following a single patient. Only study
from the past ten years (2011-2021) were screened for inclusion in the meta-analysis. The study
population consisted of 531,023 individuals (62,070 total patients with T2DM and 39,825 total
patients with sarcopenia; 6,870 patients had both sarcopenia and T2DM) with an average age of
68.27 years; 45.44% of participating individuals (241,313) were male. For all studies, the cooccurrence of sarcopenia and diabetes out of the total individuals in a given study with T2DM
(SC + T2DM/total T2DM) ranged from 7-82%. For the Asian group, the study means ranged
from 7-82%; the study means ranged from 9-37% for the Caucasian group and 14-30% for the
Hispanic group. The Asian group exhibited the greatest variation in study means whereas the
Hispanic group displayed the least study mean variation. Among the Asian studies, the study
means for China, Korea, and Japan are as follows: 0.39, 0.265, and 0.17, respectively. The
average for the studies conducted in Brazil was 0.22.
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The group means (SC + T2DM/total T2DM) for the Caucasian, Hispanic, and Asian
group were 0.23, 0.22, and 0.28, respectively. For all the studies, the average for co-occurrence
of sarcopenia and T2DM among those with T2DM was 0.26.
Out of the 26 selected studies, 18 were chosen for the Asian group. Patients were drawn
from the following countries: China (5 studies), Korea (2), Japan (7), Malaysia (1), North India
(1), Singapore (1), and Thailand (1). Of the 26 selected studies, 5 were from the Hispanic group
and were drawn from the following countries: Brazil (4) and Mexico (1). Furthermore, 3 of the
26 studies were included in the Caucasian group, with 1 study conducted in Australia, 1 in Italy,
and 1 in the UK (encompassing England, Scotland, and Wales).
Studies conducted in child populations or studies that included children were excluded;
studies with individuals older than 18 were screened. The studies selected excluded participants
with difficulties communicating, outstanding disabilities that impaired study participation, severe
cognitive impairment, notable conditions that impaired adequate nutrition, serious heart, kidney,
or liver disease, history of stroke, individuals with type 1 diabetes, difficulty ambulating, and
incomplete information; in location-specific studies, those who were not registered residents
were excluded.
Children and adolescents are still undergoing physiological changes that may confound
study variables; due to potential complications with ongoing physiological development, as well
as the later, older-aged onset of sarcopenia, children and early adolescents were excluded from
the meta-analysis. Additionally, studies conducted on patients in the United States were excluded
from the study to select more homogenous study populations.
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Further, all studies used the AWGS or EWGSOP criteria for sarcopenia diagnosis; one
study used the decrease in the ratio of appendicular lean mass (ALM)/BMI along with handgrip
strength. T2DM diagnosis was determined via blood sample, patient self-reporting, or physician
assessment during clinic visit.
We originally hypothesized that the relationship between sarcopenia and diabetes would
be stronger for Asian populations, given their higher rates of diabetes (at lower BMIs) and lower
muscle mass compared to other ethnic groups. ANOVA (analysis of variance) testing is used to
determine if a difference in means exists among three or more groups; it compares in-group and
within-group variance to generate a unified F-value and p-statistic that can be used to determine
if a difference in group means exists. ANOVA can determine if a difference exists, but additional
post hoc tests are required to determine if any differences exist between two groups. This metaanalysis analyzed three ethnic groups: Hispanic, Caucasian, and Asian, and data collected was
used to produce group means (to analyze difference of means) for each study included; therefore,
ANOVA was deemed an appropriate statistical test. Repeated paired T-tests were not utilized
due to risk of committing a Type I error.
ANOVA produced an F-statistic of 0.244 and a p-statistic of 0.785. Using an alpha level
of p = 0.05, the p-statistic obtained is greater than the stated alpha level; therefore, the results are
not statistically significant, and we fail to reject the null hypothesis. Moreover, there is no
difference in means for the co-occurrence of sarcopenia and diabetes among different ethnic
groups.
The JASP reading produce an 2 value of 0.021. The 2 value is a measure of a study’s
effect size. An 2 value of 0.01 is considered small; 0.06 is moderate; values over 0.14 represent
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a large effect size [77]. While the p-value can determine if a statistically significant difference
exists between groups, the 2 value can approximate the strength of this significance between the
groups. Therefore, the small 2 value obtained in this study suggests that the strength of the
association between ethnic group and the sarcopenia-diabetes relationship is not significantly
related. Moreover, the 2 value, as an extension of the correlation coefficient (r2), suggests that
only a low percentage of the variation in the mean values for individuals with both sarcopenia
and diabetes out of the total individuals in a study with diabetes (SC + T2DM/T2DM, the
dependent variable) can be explained by the independent variable (ethnic group).

48

49

Table 3. Study and patient characteristics from selected studies
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AWGS—Asian Working Group for Sarcopenia; EWGSOP—European Working Group on Sarcopenia in Older People; T2DM—type II diabetes mellitus; SC—
sarcopenia; SO—sarcopenic obesity

DISCUSSION
Ever-improving advances in technology and healthcare have led to dramatic shifts in
lifestyle at a global scale. Innovations in healthcare and infrastructure have contributed to
increased lifespans while a fast-paced, time-maximizing environment has given rise to altered
diets (high in processed ingredients, sugar, and saturated fats and low in fiber and essential
vitamins and minerals) and decreased physical activity. Such changes have paved the way for
two chief modern-day trends: an aging population and increased rates of overweight and obese
individuals. Sarcopenia and type II diabetes mellitus are two significant conditions that affect or
are affected by both aging and excess body weight. Sarcopenia is a condition that involves
natural, progressive loss of muscle mass, primarily as a biological result of the aging process.
Type II diabetes mellitus is a multifactorial disease that involves impaired insulin functioning; it
predominantly affects those who are overweight or obese and is becoming increasing prevalent,
especially in developed countries. Several papers have established a reciprocal relationship
between sarcopenia and diabetes in which the presence or onset of one influences or is
influenced by, the presence or onset of the other. Both conditions affect intricate metabolic
pathways and are often seen with accompanying comorbidities: heart and kidney disease,
osteoporosis, and dyslipidemia. This meta-analysis sought to explore if differences in the
sarcopenia-diabetes relationship exists among different ethnic groups, as well as to further
investigate the relationship between sarcopenia and diabetes. In this study, the strength of the
sarcopenia-diabetes relationship was quantified for each individual study as the decimal value of
the number of individuals in a given study with both sarcopenia and diabetes over the total
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number of individuals in a given study with diabetes. ANOVA was performed on group means
for the Hispanic, Caucasian, and Asian groups from 26 selected studies.
For this study, the null hypothesis is, as stated: there is no statistically significant
difference in group means among the Hispanic, Caucasian, and Asian groups. The alternative
hypothesis stated that a difference does exist in the strength of the relationship between
sarcopenia and diabetes: there is a statistically significant difference in group means among the
Hispanic, Caucasian, and Asian groups. After performing ANOVA, the p-value obtained was
greater than the accepted alpha level of p < 0.05, and we failed to reject the null hypothesis.
Thus, there is no statistically significant difference in group means among the Hispanic,
Caucasian, and Asian groups and the strength of the reciprocal sarcopenia-diabetes relationship
does not vary among different ethnic groups.
Originally, we hypothesized that the Asian group would have a stronger relationship
between sarcopenia and diabetes (statistically significant higher group mean compared to the
Hispanic and Caucasian group). Asian populations exhibit higher rates of diabetes at lower
BMIs; these populations also possess lower muscle mass and higher abdominal and visceral
body fat at a lower BMI compared to other populations. These interesting subgroup-specific
trends suggested there may be a notable difference in the co-occurrence of sarcopenia and
diabetes, especially since the two conditions have been shown to interact and influence each
other. However, no significant difference in the sarcopenia-diabetes relationship was found when
comparing the three groups.
Several explanations may further elucidate these findings. A significant amount of
variability was found within each study group, especially in the Asian group. When conducting
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ANOVA, a larger critical F-value is indicative of a lower p-value; p-values less than the
generally accepted significance level of 0.05 provide sufficient evidence to reject the null
hypothesis. The F-value is a combination of two values: the MSbetween (numerator value) and the
MSwithin (denominator value). A larger F-value is observed when the MSbetween is large
(noticeable variance between groups) and the MSwithin is small (little variance within each given
study group). In essence, a result is more probable to be statistically significant when there is
little in-group variability and greater between-group variability.
In this meta-analysis, a high degree of within-group variability resulted in a high MSwithin,
which, when inputted in the denominator, returned a low F-value that was not high enough to be
deemed statistically significant at the given significance level of p < 0.05. The difference
between groups (degree of difference in group means, which, in this study, represented the
strength of the sarcopenia-diabetes relationship) was not large enough to produce a large F-value
for the degree of within-group variability observed from the selected studies.
A primary contributor to significant in-group variation is the inherent variability
(physical, behavioral, genetic, demographic, cultural, etc.) of different study populations. The
Asian group, as with Hispanic and Caucasian groups, consist of heterogenous populations of
individuals from many different countries, regions, and environments. The classifications of
“Hispanic”, “Caucasian”, and “Asian” are far from homogenous, and some individuals who fall
under one category geographically or phenotypically may qualify for multiple categories or share
more similarities with another individual from a different category compared to an individual
from their own category. For instance, within the Asian group, there exists great phenotypical,
genotypical, geographical, environmental, historical, behavioral, and cultural differences when
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comparing different Asian ethnicities. For example, the traditional diets of the Japanese are
distinct from those of Indonesians; the cooler climate in Korea stands in stark contrast to the
warm, humid climate in the Philippines; cultural traditions (which effectively shape lifestyle,
health, and overall well-being) in India exhibit numerous differences compared to those
practiced in China. Furthermore, diets in Japan predominantly consist of rice, fish, and brothbased dishes, while those in Southeast Asian countries incorporate more tubers, starchy root
vegetables, and coconut milk. Among other factors, diet most directly impacts the presentation
and prevalence of conditions such as heart disease, obesity, and diabetes; great variability in this
factor alone is manifest in varying patterns of diabetes. Data for this meta-analysis was drawn
from several Asian countries (China, Japan, Korea, Malaysia, Singapore, North India, Singapore,
and Thailand) with multifactorial differences that cannot be understated when examining the
great degree of within-group variability obtained in this study.
Furthermore, a prominent limitation in this study is the lack of data from the African, as
well as Hispanic and Caucasian study groups. Out of the 5 African studies obtained from an
initial keyword search, none of the studies met this study’s inclusion criteria; consequently, the
group had to be removed from the meta-analysis due to lack of sufficient data. The lack of
sufficient data may be due to lack of access to adequate medical care and documentation in these
regions. Out of the 26 selected studies, 18 of these studies were from Asian countries; 5 studies
were included in the Hispanic group and 3 studies were selected for the Caucasian group. Within
the 18 Asian studies, 7 of these were conducted in Japan. Further studies in this topic would
greatly benefit from the availability of more sarcopenia and diabetes studies done in the African,
Hispanic, and Caucasian groups.
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Great variability in sample size may have contributed to non-negligible in-group
variability. Sample sizes ranged from to 76 participants to 499,046 (a national cross-sectional
study). Additionally, the study’s small effect size (2 = 0.021) indicates that a small percentage
of the variance in the dependent variable (the mean value for the quotient of those with both
sarcopenia and diabetes over the total number of individuals with diabetes for a given study) is
explained by the independent variable (ethnic group) and that the difference between groups is
not significant. Compared to the p-value, effect size better controls for the greater statistical
weight imparted by studies with larger sample sizes; it demonstrates to what extent—if shown to
be significant—a study is significant.
Of note, a general trend that was observed throughout study populations was a general
increase in sarcopenia and diabetes with age. Older study populations exhibited higher rates of
sarcopenia, diabetes, and sarcopenia with diabetes. Additionally, there appeared to be increased
incidence of sarcopenia in those populations that had diabetes. These trends further confirm the
previously established relationship between sarcopenia and diabetes.
Though no statistical differences were found between group means for the Hispanic,
Caucasian, and Asian groups, the Asian group had the highest of the group means (highest mean
percent of individuals with both sarcopenia and diabetes out of the total study individuals with
diabetes) when the selected studies were averaged.
Interestingly, the average BMI for individuals with sarcopenia was lower compared to
those without sarcopenia. This observation was consistent across the majority of the studies and
suggests a possible protective function of excess body weight in older age. The observations
from this meta-analysis are in line with other studies that have found decreased sarcopenia risk
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for older individuals with higher BMI, overweight status, or even obesity [27, 78-83]. Results
from a study by Bouillane et. al demonstrated a protective effect of fat mass in elderly,
hospitalized patients such that adiposity was associated with reduced risk of adverse health
events, thus suggesting potential positive protections against morbidity and mortality [82]. This
stands in contrast to atrophic conditions such as malnutrition, which serves as a risk factor for
sarcopenia, as well as a risk factor for increased mortality in hospitalized patients where both
conditions coincide [84, 85].
Though some studies have noted potential protective benefits against sarcopenia in obese
individuals, results regarding this apparent “age-associated obesity paradox” remain inconclusive
[80]. Benefits against sarcopenia may be more pronounced in those individuals who are
overweight (BMIs of 25.0 to 29.9), but not obese (BMIs exceeding 30) [86]. For instance, the
average BMIs of individuals included in this meta-analysis ranged from 20.5 to 28.15, with those
with sarcopenia ranging from 20.5 to 21.44. Morbidly obese individuals (BMIs greater than 30)
were not included in most studies.
Fat serves as a major energy store and appears to become increasingly more important as
individuals age. As individuals age, fat mass percentage increases as muscle mass declines. In
elderly individuals, the presence of higher adiposity may provide a more economical energy
source that is preferable to breaking down protein, the latter of which contributes to sarcopenic
progression. In women, increased fat mass may stimulate more estrogen production, which helps
to counteract age-associated declines in sex hormones that contribute to decreased muscle mass.
However, extremely excessive adiposity (as seen in individuals who are morbidly obese) may
contribute to the previously mentioned cytokine storm, which facilitates a low-grade
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inflammatory state conducive to the development or exacerbation of metabolic disturbances and
comorbidities. Moreover, excess fat mass in older age may be protective, but up to a certain
extent, as extreme excess adiposity comes with a range of accompanying metabolic shifts that
may interfere with muscle synthesis and negate or balance out any benefits conferred from the
excess adiposity itself.
Future studies are advised to draw from a larger sample size and should strive to increase
the number of studies from the Caucasian, African, and Hispanic groups, if or when available.
Inclusion criteria should be more stringent to address the limitations due to variation that were
observed in this study.
Though the original study sought to explore potential topics in personalized medicine,
given a statistically significant difference was observed, the lack of statistical significance among
different ethnic groups provides a notable point of interest. Certain diseases such as diabetes,
hypertension, and osteoporosis demonstrate ethnic trends in presentation, prevalence, and
severity. Though this may be true when observing a certain condition by itself, analyzing
multiple conditions together does not translate to statistically significant differences in the
relationship between the two conditions. Moreover, in this meta-analysis, though sarcopenia and
diabetes appeared more prevalent in Asian populations compared to other ethnic groups at a
lower BMI, this does not necessarily translate to a stronger sarcopenia-diabetes relationship
when the two conditions are analyzed together.
The reciprocal sarcopenia-diabetes relationship is influenced by numerous factors: diet,
environment, physical activity, etc. The interplay of multiple factors makes it difficult to isolate
the influence of one disease compared to the other, as well as the extent of the contribution of
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one factor or condition to the overall relationship. Additionally, inherent in-group variations
further complicate the analysis such that any statistical difference between groups becomes
difficult to detect, if present.
The absence of a statistically significant difference in the sarcopenia-diabetes relationship
among different ethnic groups suggests an increased homogenization in the presentation, trends,
and prevalence of comorbid metabolic diseases. Lifestyle and diet are among two of the chief
factors in sarcopenia and diabetes development and progression. Diet and physical activity
remain two important contributing factors to sarcopenia onset and progression. Physical activity
alone has been shown to reduce sarcopenia risk, as well as the risk for other comorbidities
including T2DM, high cholesterol, heart disease, hypertension, and osteoporosis [87-89].
Though it is possible that genetic variations shared by similar ethnic groups may contribute to
altered metabolic patterns (for instance, some increasing metabolic thrift while others decreasing
it and thus predisposing some groups to certain diseases over others), these differences are
superseded when considering the complex, reciprocal, and inevitable interplay of multiple cooccurring metabolic morbidities in a modern landscape. Increasingly, developing countries have
transitioned from traditional diets to more westernized fare while developed countries have
continued to increase the production and consumption of western fare. Not only have
technology, goods, and cultures transcended geographical boundaries and diffused globally, but
also lifestyles. Typical modern diets are higher in processed carbohydrates, sugar, sodium,
saturated fats, and empty calories while lower in fiber and essential nutrients compared to
traditional fare. Combined with decreased physical activity, increased sedentation, and stress,
these trends have contributed to increased rates of overweightness and obesity in both
59

developing and developed countries. Identification of current global health trends is integral in
developing preventative lifestyle modifications that can be combined with healthcare technology.
In summary, sarcopenia and diabetes have been shown to demonstrate a reciprocal
relationship in which the incidence of one influences or is influenced by the other. This metaanalysis has shown that, although differences in the prevalence of sarcopenia and diabetes have
been demonstrated, there is no significant difference in the strength of the sarcopenia-diabetes
relationship among different ethnic groups. Both sarcopenia and diabetes affect a substantial
portion of the world population and are major contributors to increasing healthcare costs and
decreased quality of life. Metabolic diseases such as sarcopenia and diabetes are becoming
increasingly critical conditions to address as populations age and undergo increased
homogenization in modern lifestyle and diet transitions. The findings from this study further
corroborate the increasing need to address lifestyle and diet changes in the face of modern trends.
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